Canadian manufacturer Medicago’s COVID-19 vaccine showing strong efficacy - Globalnews.ca | Canada News Media
Connect with us

Business

Canadian manufacturer Medicago’s COVID-19 vaccine showing strong efficacy – Globalnews.ca

Published

 on


A home-grown COVID-19 vaccine candidate could soon be on the market, with Quebec-based Medicago’s latest data showing promising results. The biopharmaceutical manufacturer, which says its product showed 75.3 per cent efficacy against the Delta variant, said it plans to “imminently” file a final regulatory submission to Health Canada.

“I think the results that we have are really exciting and really interesting,” said Brian Ward, medical officer for Medicago.

The data published by Medicago showed efficacy against COVID-19 variants, such as Delta, which is globally the dominant strain. The company said in a press release that other vaccines which are currently in use did not have Phase 3 trials with the Delta variant. Overall, the vaccine had a 71 per cent efficacy against all variants, but the trials occurred before the appearance of the largely unknown Omicron variant.

“Our vaccine was actually challenged by these much more complicated, mutated viruses,” Ward said. “The overall efficacy that we achieved (in) that changed environment was actually really exciting for us.”

Read more:

Medicago clinical trial participants want equal access to Quebec COVID-19 vaccine passport

The vaccine, which is plant-based, “uses living plants as bioreactors to produce a non-infectious particle that mimics the target virus, without the use of any viruses,” according to the company. The technology produces Virus-Like Particles (VLP) for the protein vaccines, which mimic the actual coronavirus and can be easily picked up by the immune system. VLPs are not infectious and unable to replicated.

Medicago’s COVID-19 vaccine uses an adjuvant, which is a drug, substance or combination of substances used to amplify a vaccine effectiveness. Ward said Medicago’s vaccine candidate will also come with a lot of firsts.

“It will probably be the first virus-like particle vaccine for COVID,  the first Canadian based vaccine for COVID, and it will be the world’s first plant-based vaccine for human use of any kind,” he said.






2:00
Plants key for Canada’s COVID-19 vaccine contender


Plants key for Canada’s COVID-19 vaccine contender – Jan 11, 2021

No serious adverse events were reported during the trials and the Medicago’s trials, which took place in six countries, saw over 24,000 participants participate. Half used the Canadian company’s vaccine candidate with the others using a placebo. The subjects were all 18 and older and were given two doses of the vaccine 21 days apart.

Read more:

Canada’s Medicago says its COVID-19 vaccine shows promising antibody results in trial

Innovation Minister Francois-Philippe Champagne told the Canadian Press that he was impressed by how Canada has built up vaccine manufacturing infrastructure in a short time. The Canadian government has invested $173 million in Medicago’s vaccine candidate. Medicago’s current production facility is based in North Carolina, but the company is in the midst of building a global production facility in Quebec by the end of 2023.

“We’re seeing a renewed interest in bringing some of that (manufacturing) capacity back into the country,” Ward said. “I think there is a commitment.”

The vaccine was developed in partnership with Medicago British-American vaccine giant GlaxoSmithKline (GSK). For Ward, the phase 3 results show the power of Canadian ingenuity and research if provided the correct resources.

“We’re a small group of people, we’re a small company. And I think probably by a fair stretch we’re one of the smallest companies to successfully run a study of this size and complexity,” he said.






4:28
The made-in-Quebec COVID-19 vaccine


The made-in-Quebec COVID-19 vaccine – Jan 14, 2021

The landscape for vaccines in Canada has shifted from earlier in the pandemic when the country was struggling to secure doses. Now, with over 80 per cent of the population fully vaccinated and vaccines going to waste, Ward thinks Medicago’s vaccine candidate can play a role domestically, albeit a small one.

“Vaccine booster doses are needed to protect people,” Ward said. “There is data that shows mixing vaccines work well, too. I see that being the Canadian application.”

Canada’s National Advisory Committee on Immunization has “strongly” recommended a COVID-19 vaccine booster shot for people 50 and older. The committee also recommended that booster shots of an mRNA vaccine be offered to adults ages 18 to 49 at least six months after their second dose.

Read more:

Canada’s COVID-19 vaccine contender: Medicago’s breakthrough, ties to Big Tobacco and warnings a pandemic was coming

Health Canada does have an agreement in place with Medicago for an initial purchase of 20 million doses with an ability to increase to 76 million, if needed. But, to Ward and Medicago, they think that their best way forward will be to provide global vaccine relief after receiving authorization.

“There is a global need for vaccines,” Ward said. “Less than one half of the world’s population has had access to vaccines so far so that there are still billions of doses that are needed. We would like to be able to contribute.”

Even the vaccines produced for Canadians can be used globally depending on the discretion of the federal government, according to Ward.

“Canada would make the decision on how to use those vaccines, and we are in negotiation with other countries,” he said.

with files from the Canadian Press

© 2021 Global News, a division of Corus Entertainment Inc.

Adblock test (Why?)



Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Dollarama keeping an eye on competitors as Loblaw launches new ultra-discount chain

Published

 on

 

Dollarama Inc.’s food aisles may have expanded far beyond sweet treats or piles of gum by the checkout counter in recent years, but its chief executive maintains his company is “not in the grocery business,” even if it’s keeping an eye on the sector.

“It’s just one small part of our store,” Neil Rossy told analysts on a Wednesday call, where he was questioned about the company’s food merchandise and rivals playing in the same space.

“We will keep an eye on all retailers — like all retailers keep an eye on us — to make sure that we’re competitive and we understand what’s out there.”

Over the last decade and as consumers have more recently sought deals, Dollarama’s food merchandise has expanded to include bread and pantry staples like cereal, rice and pasta sold at prices on par or below supermarkets.

However, the competition in the discount segment of the market Dollarama operates in intensified recently when the country’s biggest grocery chain began piloting a new ultra-discount store.

The No Name stores being tested by Loblaw Cos. Ltd. in Windsor, St. Catharines and Brockville, Ont., are billed as 20 per cent cheaper than discount retail competitors including No Frills. The grocery giant is able to offer such cost savings by relying on a smaller store footprint, fewer chilled products and a hearty range of No Name merchandise.

Though Rossy brushed off notions that his company is a supermarket challenger, grocers aren’t off his radar.

“All retailers in Canada are realistic about the fact that everyone is everyone’s competition on any given item or category,” he said.

Rossy declined to reveal how much of the chain’s sales would overlap with Loblaw or the food category, arguing the vast variety of items Dollarama sells is its strength rather than its grocery products alone.

“What makes Dollarama Dollarama is a very wide assortment of different departments that somewhat represent the old five-and-dime local convenience store,” he said.

The breadth of Dollarama’s offerings helped carry the company to a second-quarter profit of $285.9 million, up from $245.8 million in the same quarter last year as its sales rose 7.4 per cent.

The retailer said Wednesday the profit amounted to $1.02 per diluted share for the 13-week period ended July 28, up from 86 cents per diluted share a year earlier.

The period the quarter covers includes the start of summer, when Rossy said the weather was “terrible.”

“The weather got slightly better towards the end of the summer and our sales certainly increased, but not enough to make up for the season’s horrible start,” he said.

Sales totalled $1.56 billion for the quarter, up from $1.46 billion in the same quarter last year.

Comparable store sales, a key metric for retailers, increased 4.7 per cent, while the average transaction was down2.2 per cent and traffic was up seven per cent, RBC analyst Irene Nattel pointed out.

She told investors in a note that the numbers reflect “solid demand as cautious consumers focus on core consumables and everyday essentials.”

Analysts have attributed such behaviour to interest rates that have been slow to drop and high prices of key consumer goods, which are weighing on household budgets.

To cope, many Canadians have spent more time seeking deals, trading down to more affordable brands and forgoing small luxuries they would treat themselves to in better economic times.

“When people feel squeezed, they tend to shy away from discretionary, focus on the basics,” Rossy said. “When people are feeling good about their wallet, they tend to be more lax about the basics and more willing to spend on discretionary.”

The current economic situation has drawn in not just the average Canadian looking to save a buck or two, but also wealthier consumers.

“When the entire economy is feeling slightly squeezed, we get more consumers who might not have to or want to shop at a Dollarama generally or who enjoy shopping at a Dollarama but have the luxury of not having to worry about the price in some other store that they happen to be standing in that has those goods,” Rossy said.

“Well, when times are tougher, they’ll consider the extra five minutes to go to the store next door.”

This report by The Canadian Press was first published Sept. 11, 2024.

Companies in this story: (TSX:DOL)

Source link

Continue Reading

Business

U.S. regulator fines TD Bank US$28M for faulty consumer reports

Published

 on

 

TORONTO – The U.S. Consumer Financial Protection Bureau has ordered TD Bank Group to pay US$28 million for repeatedly sharing inaccurate, negative information about its customers to consumer reporting companies.

The agency says TD has to pay US$7.76 million in total to tens of thousands of victims of its illegal actions, along with a US$20 million civil penalty.

It says TD shared information that contained systemic errors about credit card and bank deposit accounts to consumer reporting companies, which can include credit reports as well as screening reports for tenants and employees and other background checks.

CFPB director Rohit Chopra says in a statement that TD threatened the consumer reports of customers with fraudulent information then “barely lifted a finger to fix it,” and that regulators will need to “focus major attention” on TD Bank to change its course.

TD says in a statement it self-identified these issues and proactively worked to improve its practices, and that it is committed to delivering on its responsibilities to its customers.

The bank also faces scrutiny in the U.S. over its anti-money laundering program where it expects to pay more than US$3 billion in monetary penalties to resolve.

This report by The Canadian Press was first published Sept. 11, 2024.

Companies in this story: (TSX:TD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version